Response to Letter Regarding Article, "Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial"

Affiliations

¹ Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
² Antimicrobial Resistance Research Center, Department of Infectious Diseases, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
³ Department of Clinical Pharmacy, Faculty of Pharmacy, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
⁴ Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville, Florida.
⁵ Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
⁶ Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran. Electronic address: drmsrezaii@yahoo.com.

Comment

Leila Shahbaznejad et al. Clin Ther. 2021 Sep.

. 2021 Sep;43(9):1624-1626.

doi: 10.1016/j.clinthera.2021.07.006. Epub 2021 Aug 5.

¹ Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
² Antimicrobial Resistance Research Center, Department of Infectious Diseases, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
³ Department of Clinical Pharmacy, Faculty of Pharmacy, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
⁴ Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville, Florida.
⁵ Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
⁶ Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran. Electronic address: drmsrezaii@yahoo.com.

No abstract available

Comment on

Ivermectin for Coronavirus Disease 2019: Yet to Be Well Evaluated Before Clinical Use.
Hagiya H, Otsuka F. Hagiya H, et al. Clin Ther. 2021 Sep;43(9):1622-1623. doi: 10.1016/j.clinthera.2021.07.007. Epub 2021 Jul 12. Clin Ther. 2021. PMID: 34362568 Free PMC article. No abstract available.

1. Shahbaznejad L, Davoudi AR, Eslami G, et al. Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial. Clinical Therapeutics. 2021 - PMC - PubMed
1. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM, Chik TS, Lau DP. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases. 2020;20:565–574. - PMC - PubMed
1. Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA. 2020;323:2249–2251. - PubMed
1. Bernheim A, Mei X, Huang M, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology. 2020 - PMC - PubMed
1. Gorial FI, Mashhadani S, Sayaly HM, Dakhil BD, AlMashhadani MM, Aljabory AM, Abbas HM, Ghanim M, Rasheed JI. Medrxiv. 2020 Jan 1. Effectiveness of ivermectin as add-on therapy in COVID-19 management (pilot trial)https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1 Available at: - DOI